Immunogenic antigens as therapeutic targets against myeloid leukaemic cells

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 850-851

  Hofmann, Susanne ^a   Greiner, Jochen ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER TESTIS ANTIGEN; GEMTUZUMAB OZOGAMICIN; HISTAMINE; INTERLEUKIN 2; LEUKEMIA ANTIGEN; RITUXIMAB; SPERM ASSOCIATED ANTIGEN 9; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DRUG PROTEIN BINDING; DRUG TARGETING; EDITORIAL; HUMAN; HUMORAL IMMUNITY; LEUKEMIA CELL; LEUKEMIA REMISSION; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; VACCINATION;

EID: 77952953502     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.013     Document Type: Editorial

References (11)

1. Greiner J., Bullinger L., Guinn B.A., Dohner H., Schmitt M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 2008, 14(22):7161-7166.
2. Schmitt M., Schmitt A., Rojewski M.T., Chen J., Giannopoulos K., Fei F., et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008, 111(3):1357-1365.
3. Greiner J., Schmitt A., Giannopoulos K., Rojewski M.T., Götz M., Funk I., et al. High dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM). Haematologica 2010, [Epub ahead of print].
4. Rezvani K., Yong A.S., Mielke S., Savani B.N., Musse L., Superata J., et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111(1):236-242.
5. Keilholz U., Letsch A., Busse A., Asemissen A.M., Bauer S., Blau I.W., et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113(June (26)):6541-6548.
6. Rojas J.M., Knight K., Wang L., Clark R.E. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007, 21(11):2287-2295.
7. Greiner J., Li L., Ringhoffer M., Barth T.F., Giannopoulos K., Guillaume P., et al. Identification and characterization of epitopes the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005, 106(August (3)):938-945.
8. Elisseeva O.A., Oka Y., Tsuboi A., Ogata K., Wu F., Kim E.H., et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002, 99(9):3272-3279.
9. Kanojia D., Garg M., Saini S., Agarwal S., Kumar R., Suri A. Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. Leuk Res 2010, 34(7):858-863.
10. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6(9):1018-1023.
11. Brune M., Castaine S., Catalano J., Gehlsen K., Ho A.D., Hofmann W.K., et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006, 108(July (1)):88-96.